Welcome to our dedicated page for Nephros SEC filings (Ticker: NEPH), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Nephros Inc. filings document formal disclosures for a water technology company selling filtration solutions to medical and commercial markets. Recent 8-K reports furnish operating results and financial condition updates, Regulation FD presentations, and material event disclosures tied to the company's product, service, and education strategy.
The filing record also includes a material definitive agreement with Medica S.p.A. covering license and supply arrangements for filtration products based on Medisulfone ultrafiltration technology. These disclosures describe contractual rights, supply obligations, product commercialization arrangements, and related public-company reporting matters.
Nephros (NEPH) Form 4: A director reported acquiring 1,622 shares of common stock on 11/10/2025 at $0, held directly following the transaction.
The reporting person also holds a stock option to buy 13,229 shares at $4.49, expiring 08/11/2035. The option vests as to 4,410 shares on 6/16/25, 4,410 shares on 6/16/26, and 4,409 shares on 6/16/27.
Nephros, Inc. (NEPH) filed a Form 4 showing insider activity. A director reported acquiring 8,036 shares of common stock on 11/10/2025 at $0, bringing direct beneficial ownership to 122,881 shares following the transaction. The filing also lists multiple outstanding stock options with various exercise prices and expirations, with examples including options exercisable at $5.5755 expiring 08/10/2028 and at $2.14 expiring 05/14/2034.
Nephros (NEPH) Form 4: A director reported acquiring 5,391 shares of common stock on 11/10/2025 at a price of $0. Following this transaction, the director beneficially owned 131,272 shares directly.
The filing also lists outstanding stock options: 7,323 options with a $2.14 exercise price expiring 05/14/2034 and 7,050 options with a $1.47 exercise price expiring 01/01/2035. The vesting schedules include 2,441 shares on each of 5/14/24, 5/14/25, and 5/14/26 for the first grant, and 2,350 shares on each of 1/1/25, 1/1/26, and 1/1/27 for the second.
Nephros (NEPH) reported strong Q3 2025 results, driven by higher programmatic activity and service growth. Net revenue rose to $4.764M (up 35% year over year), with gross margin steady at 61%. Operating income improved to $0.314M, and net income reached $0.337M (basic and diluted EPS $0.03).
For the nine months, revenue increased to $14.060M (up 37%), gross margin expanded to 63%, and the company swung to $1.132M in net income from a prior loss. Operating cash flow was $1.415M, lifting cash to $5.171M and working capital to $8.239M. SG&A and R&D rose with higher commissions, bonus accruals, and salaries, while interest income increased.
The company notes customer concentration (top accounts comprised 46% of Q3 revenue) and continues to remediate a previously identified revenue recognition control weakness under ASC 606. As of November 3, 2025, 10,626,683 common shares were outstanding.
Lisa Nettis, a director of Nephros Inc. (NEPH), acquired 13,229 stock options on 08/11/2025 with an exercise price of $4.49 per share. The options convert into 13,229 shares of common stock and have an expiration date of 08/11/2035.
The filing discloses a vesting schedule: 4,410 options vest on each of 6/16/2025 and 6/16/2026, and 4,409 vest on 6/16/2027. The Form 4 was executed by Edward Peilen as attorney-in-fact on 08/13/2025 and lists Nettis as a director.
Nephros, Inc. furnished a press release disclosing its second quarter 2025 financial results and included that press release as Exhibit 99.1 to this Form 8-K. The company explicitly stated the exhibit is furnished, not filed, and therefore is not subject to liability under Section 18 of the Exchange Act nor automatically incorporated by reference into other filings unless expressly stated. The report was signed on behalf of the registrant by the Chief Financial Officer.